SRI-31255
SRI-31255 is an orally active LRRK2 inhibitor with IC50 values of 520 and 427 nM for human wild-type (WT) and mutant G2019S, respectively. SRI-31255 exerts neuroprotective effects by binding to the ATP-binding pocket of LRRK2, inhibiting kinase activity. SRI-31255 can be used as a lead compound for the development of LRRK2-targeted drugs for the treatment of Parkinson's disease[1].
Product Specifications
CAS Number
[905580-86-1]
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
LRRK2
Related Pathways
Autophagy
Field of Research
Neurological Disease
Smiles
C1(N[C@@H](CC2)C3=C2C=CC=C3)=C4C(NC=C4)=NC=N1
Molecular Formula
C15H14N4
Molecular Weight
250.30
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501
References & Citations
[1]Moukha-Chafiq O, et al. Discovery of a Chiral 2,4-Substituted Pyrrolo[2,3-d]pyrimidine as a Potent, Selective, and Orally Bioavailable LRRK2 Inhibitor. J Med Chem. 2025 May 22;68 (10) :9926-9946.
Shipping Conditions
Room temperature
Scientific Category
Reference compound2
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15205280 1 Vial
Lentiviral mouse Treml1 shRNA (UAS) - Lentiviral mouseTreml1 shRNA (UAS, GFP) (25)
Ask
View Details 